Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.56 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA4 | P22748 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314075 | 0.88 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL6315346 | 0.87 | PTGS2 (0.52) | PTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL6314804 | 0.86 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL6315488 | 0.85 | PTGS2 (0.60) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6314798 | 0.85 | PTGS2 (0.52) | PTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL6315363 | 0.84 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL6314404 | 0.78 | PTGS2 (0.54) | PTGS2PTGS1 | |
| SCHEMBL5204024 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6313700 | 0.77 | PTGS2 (0.73) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6315461 | 0.76 | PTGS2 (0.55) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951876-B2 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6603008-B1 | Inhibit the biosynthesis of prostaglandins by intervention of the action of the enzyme cyclooxygenase on arachidonic acid | PFIZER INC. | 2003-08-05 | — | — | US | disclosed |
| US-20030144280-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER INC. (US) | 2003-07-31 | — | — | US | disclosed |
| EP-1104760-B1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER PROD INC (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1104760-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144280-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PTGS1, PTGS2, SULT2A1 | PTGS2 2/4885PTGS1 1/4885CA1 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.